New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
The management of atrial fibrillation (AF) is plagued by, among other things, limitations in the efficacy, tolerance, and safety of currently available agents for the conversion of AF to sinus rhythm and for the maintenance of sinus rhythm. This review describes some of the most promising approaches to new therapies that may overcome some of the limitations of our current therapies. The agents we have chosen to review are representative of these new approaches and have completed their phase III trials and have submitted an application for approval for release by regulatory agencies or have almost completed their phase III trials and appear likely to submit for approval in the not to distant future.
Morrow
John P
JP
The Division of Cardiology, Department of Medicine, Columbia University, New York, NY, USA.
Cannon
Christopher P
CP
Reiffel
James A
JA
D000638:Amiodarone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D000077764:Dronedarone; D004341:Drug Evaluation / Q000639:trends*; D006339:Heart Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D012849:Sinoatrial Node / Q000187:drug effects / Q000503:physiopathology*; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone